

IN THE CLAIMS:

1-60. Canceled.

61. (Currently amended) ~~The isolated antibody of claim 60, An isolated antibody, or a fragment or derivative thereof, which binds to an eight amino acid epitope consisting of a sequence QSRDTEVL (SEQ ID NO: 1) present within amino acids 175-536 of a human ECRTP/DEP-1 density enhanced phosphatase-1 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4, in a diluent or excipient pharmaceutically acceptable in humans.~~

62. (Previously canceled)

63-67. Canceled.

68. (Currently amended) ~~A[[n]] composition comprising a therapeutically effective amount of an isolated antibody, or a fragment or derivative thereof, which specifically binds an extracellular domain of an ECRTP/DEP-1 density enhanced phosphatase-1 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4 in a diluent or excipient pharmaceutically acceptable in humans, and wherein the antibody, fragment, or derivative thereof has activity in modulating composition inhibits angiogenesis, in a diluent or excipient pharmaceutically acceptable in humans.~~

69. (Currently amended) ~~The isolated antibody composition of claim 68, or a fragment or derivative thereof, wherein the antibody, fragment, or derivative thereof has activity in modulating inhibiting angiogenesis in an assay selected from the group consisting of a planar endothelial migration assay, an *in situ* transfection assay for migration, a cornea pocket angiogenesis assay, a chick chorioallantoic membrane assay, a proliferation assay, and an endothelial wound closure assay.~~

70. (Currently amended) ~~The isolated antibody fragment composition of claim 68, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.~~

71. (Currently amended) ~~The isolated antibody composition of claim 68, which wherein the antibody, fragment, or derivative thereof is a monoclonal antibody, or a fragment or derivative thereof.~~

72. (Currently amended) The ~~isolated antibody composition~~ of claim 71, wherein the antibody, fragment, or derivative thereof is human or humanized.

73. Canceled.

74. (Currently amended) The ~~isolated antibody composition~~ of claim 68, further having wherein the antibody, fragment, or derivative thereof has a binding specificity of a monoclonal antibody produced by a hybridoma cell line having American Type Culture Collection (ATCC) accession number HB12570.

75. (Currently amended) The ~~isolated antibody composition~~ of claim 68, wherein the ~~monoclonal~~ antibody is a monoclonal antibody produced by a hybridoma cell line having American Type Culture Collection (ATCC) accession number HB12570.

76. (Currently amended) A[[n]] ~~composition comprising a therapeutically effective amount of an~~ isolated antibody, or a fragment or derivative thereof, which specifically binds an epitope present within amino acids 175-536 of a human ECRTP/DEP-1 density enhanced phosphatase-1 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4 ~~in a diluent or excipient pharmaceutically acceptable in humans, and wherein the antibody, fragment, or derivative thereof composition inhibits has activity in modulating angiogenesis, in a diluent or excipient pharmaceutically acceptable in humans.~~

77. (Currently amended) The ~~isolated antibody composition~~ of claim 76, or a fragment or derivative thereof, wherein the antibody, fragment, or derivative thereof has activity in modulating inhibiting angiogenesis in an assay selected from the group consisting of a planar endothelial migration assay, an *in situ* transfection assay for migration, a cornea pocket angiogenesis assay, a chick chorioallantoic membrane assay, a proliferation assay, and an endothelial wound closure assay.

78. (Currently amended) The ~~isolated antibody fragment composition~~ of claim 76, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.

79. (Currently amended) The isolated antibody composition of claim 76, which wherein the antibody, fragment, or derivative thereof is a monoclonal antibody, or a fragment or derivative thereof.

80. (Currently amended) The isolated antibody composition of claim 79, which wherein the monoclonal antibody is monoclonal antibody ECRTPAb-1, having a molecular weight of about 150 kDa and which specifically binds to an epitope present within amino acids 175-536 of a human ECRTP/DEP-1 density enhanced phosphatase-1 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4.

81. (Currently amended) The isolated antibody composition of claim 79, wherein the antibody, fragment, or derivative thereof is human or humanized.

82. Canceled.

83. (Currently amended) A[[n]] composition comprising a therapeutically effective amount of an isolated antibody, or a fragment or derivative thereof, which specifically binds to an epitope present within amino acids 324-331 in an extracellular domain of an of a human ECRTP/DEP-1 density enhanced phosphatase-1 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4 in a diluent or excipient pharmaceutically acceptable in humans, the epitope comprising the sequence QSRDTEVL (SEQ ID NO: 1), wherein the antibody, fragment, or derivative thereof has activity in modulating composition inhibits angiogenesis.

84. (Currently amended) The isolated antibody composition of claim 83, or a fragment or derivative thereof, wherein the antibody, fragment, or derivative thereof has activity in modulating inhibiting angiogenesis in an assay selected from the group consisting of a planar endothelial migration assay, an *in situ* transfection assay for migration, a cornea pocket angiogenesis assay, a chick chorioallantoic membrane assay, a proliferation assay, and an endothelial wound closure assay.

85. (Currently amended) The isolated antibody fragment composition of claim 83, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment, an F(v) fragment, and an single chain fragment variable (scFv) fragment.

86. (Currently amended) The ~~isolated antibody composition~~ of claim 83, which wherein the antibody, or the fragment or derivative thereof, is a monoclonal antibody or a fragment or derivative thereof.

87. (Currently amended) The ~~isolated antibody composition~~ of claim 86, wherein the antibody, fragment, or derivative thereof is human or humanized.

88. Canceled.

89. (Previously presented) An isolated antibody having a binding specificity of an antibody produced by a hybridoma cell line having American Type Culture Collection (ATCC) accession number HB12570.

90-92. Canceled.

Please add the following new claims:

93. (New) The isolated antibody, or the fragment or derivative thereof, of claim 61, wherein the isolated antibody, or the fragment or derivative thereof, is a monoclonal antibody, or a fragment or derivative thereof.

94. (New) The isolated antibody, or the fragment or derivative thereof, of claim 93, wherein the antibody, or the fragment or derivative thereof, is human or humanized.

95. (New) A composition for modulating angiogenesis, the composition comprising:

(a) a therapeutically effective amount of the isolated antibody, or the fragment or derivative thereof, which binds to an eight amino acid epitope consisting of a sequence QSRDTEVL (SEQ ID NO: 1) present within amino acids 175-536 of a human ECRTP/DEP-1 density enhanced phosphatase-1 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 4; and

(b) a diluent or excipient pharmaceutically acceptable in humans.

96. (New) The composition of claim 95, wherein the isolated antibody, or the fragment or derivative thereof, is a monoclonal antibody, or a fragment or derivative thereof.

97. (New) The composition of claim 96, wherein the antibody, or the fragment or derivative thereof, is human or humanized.